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The diagnosis of pulmonary embolism (PE) is frequently considered in patients presenting to the emergency
department or when hospitalized. Although early treatment is highly effective, PE is underdiagnosed and, therefore,
the disease remains a major health problem. Since symptoms and signs are non specific and the consequences of
anticoagulant treatment are considerable, objective tests to either establish or refute the diagnosis have become a
standard of care. Diagnostic strategy should be based on clinical evaluation of the probability of PE. The accuracy of
diagnostic tests for PE are high when the results are concordant with the clinical assessment. Additional testing is
necessary when the test results are inconsistent with clinical probability. The present review article represents the
consensus-based recommendations of the Interdisciplinary Association for Research in Lung Disease (AIMAR)
multidisciplinary Task Force for diagnosis and treatment of PE. The aim of this review is to provide clinicians a
practical diagnostic and therapeutic management approach using evidence from the literature.
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Pulmonary embolism (PE) is an acute and potentially
fatal condition in which embolic material, usually a
thrombus originating from one of the deep veins of the
legs or pelvis, blocks one or more pulmonary arteries,
causing impaired blood flow and increased pressure to
the right cardiac ventricle. Pulmonary embolism and
deep vein thrombosis are considered to be two manifes-
tations of the same condition, venous thromboembolism,
which is the third most common cardiovascular disorder
in industrialized countries [1,2]. PE is difficult to diag-
nose because symptoms are non-specific and clinical
presentation of patients with suspected PE varies widely
from patients who are asymptomatic to those in cardio-
genic shock.
In October 2011 the Interdisciplinary Association for
Research in Lung Disease (AIMAR) established a Task
Force for diagnosis and treatment of PE with multidis-
ciplinary representation including 3 pulmonologists, 3* Correspondence: massimo.pistolesi@unifi.it
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stated.internists, 2 emergency care physicians, 1 cardiologist, 1
radiologist and 1 nuclear medicine physician. The mem-
bers of the Task Force have engaged in interdisciplinary
collaborations regarding the diagnostic strategies and treat-
ment of PE. The interdisciplinary organization structure of
the present Task Force was designed to support the need
of a multidisciplinary approach in the early diagnosis of the
disease. The Task Force was asked to structure its recom-
mendations on the diagnosis of PE through a multidiscip-
linary process that can be dynamically adapted to a rapid
changing and increasingly personalized delivery of health
care within a structured framework. The Task Force
reviewed the literature, and discussed clinical practices
in Italy on meetings and conference calls. No attempt
was made to grade evidence or recommendations. The
present article represents the recommended consensus-
based guidelines of the Task Force.Epidemiology
Symptomatic venous thromboembolism occurs in 1–2
per 1,000 adults each year, with about a third presenting
with PE [1,2]. The incidence of PE correlates strongly with
age, being extremely rare in childhood (5 per 100,000 ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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500–600 cases per 100,000 in older (> 75 years) age [1-3].
Overall, men and women are affected equally, but women
of reproductive age have slightly higher rates of PE be-
cause of the association between the disease and preg-
nancy, and the increased risk conferred by the use of oral
contraceptives [1,4]. In older age, the incidence of PE is
higher in men than in women [2]. PE-related mortality
can be as high as 25% if untreated [2], however, with ad-
equate anticoagulant therapy, this rate decreases to about
2–8% in the 3 months following diagnosis [5,6]. However,
the actual figures could be higher than those generally re-
ported because patients who die before diagnosis are usu-
ally not included in clinical studies. In the acute phase, i.e.
the first month after diagnosis, mortality is influenced by
the presence of hemodynamic instability, underlying co-
morbidities, and immobility [5]. In the long term, i. e. ≥
1 year after diagnosis, due to comorbidities that are strong
predictors of mortality [7] such as malignancy, left-sided
congestive heart failure, and chronic lung disease, mortal-
ity can reach 24–27%. Malignancy is the most frequent
cause of death (35–45%), whereas recurrent PE accounts
for 2.5–7.0% [7].
Risk factors
Pulmonary embolism is currently considered to be the re-
sult of an interaction between patient-related and setting-
related risk factors. Patient-related predisposing factors
are usually permanent, whereas setting-related risk factors
are more often temporary. Commonly, more than one risk
factor is present, illustrating that PE is a multicausal dis-
ease. However, PE can occur in patients without any iden-
tifiable predisposing factors.
Inherited risk factors
Prothrombotic inherited risk factors are associated with
either reduced levels of anticoagulant proteins or in-
creased levels or function of coagulation proteins. In the
general population, thrombophilic abnormalities vary in
prevalence and also in the risk of PE that they convey.
Generally, the overall absolute risk of PE is low, regard-
less of the increased relative risk caused by the presence
of a thrombophilic factor [2]. Deficiencies of natural co-
agulation inhibitors, such as antithrombin, protein C
and protein S, are strong risk factors for PE, but these
deficiencies are rare and only account for 1% of all cases of
PE. Factor V Leiden and prothrombin (factor II) G20210A
are the two more common genetic variants that have been
consistently found to be associated with PE, but still only
explain a small proportion of PE cases. The search for new
genetic variants associated with PE is ongoing and, at the
present, the impact of identification of new genetic risk fac-
tors on the management of individual patients is unclear.
More insight into how genetic risk factors are involved inPE may enable personalized risk profiling in selected pa-
tients. However, to be applicable in a clinical setting, the
assays must be fast, affordable, and able to detect a combin-
ation of clinically relevant genetic factors.
Acquired risk factors
Several acquired risk factors for PE have been identified.
The highest risk for PE is conferred by surgery (particu-
larly orthopedic surgery, surgery for cancer, and neuro-
surgery), history of previous venous thronboembolism,
immobility for more than 48 h, hospitalization, infection,
and cancer [8-14]. In the Prospective Investigative Study
of Acute Pulmonary Embolism Diagnosis (PISA-PED), at
least one of these risk factors was present in more than
80% of patients with established PE and in about 70% of
those without PE [8]. The risk of developing symptom-
atic PE is 7 fold higher among patients with cancer than
in those without cancer and approximately 10% of all
PEs are secondary to a known cancer [11]. In a large
population-based study, confirmed symptomatic PEs were
diagnosed within 2 yrs in 1.6% of 235,149 cancer cases
[11], and metastatic disease at the time of diagnosis was
the strongest predictor of PE [11]. All haematological and
solid tumour types have been associated with PE but the
PE risk varies among the various types of cancer. Blom
et al. [11] observed the highest risk of PE adjusted for age
and sex among patients with haematological malignancies
(odds ratio: 28), lung cancer (odds ratio: 22) and gastro-
intestinal cancer (odds ratio: 20). Adjusting for age, race
and stage, diagnosis of PE was a significant predictor of
death during the first year for all cancer types [15]. In pa-
tients with PE, the prevalence of concomitant cancer, not
known before the diagnosis of PE and discovered by rou-
tine investigation at the time of PE diagnosis, varies be-
tween 4% and 12% [16]. The risk of occult cancer is
increased three- to four-fold in patients with idiopathic PE
compared with secondary PE [16]. Considering the high
incidence of cancer in the initial months following diagno-
sis PE, screening for an underlying malignancy may be
clinically relevant in selected cases.
About two-thirds of PE cases occur during pregnancy
and one-third post partum. A recent study showed that
the risk of PE was increased five-fold during pregnancy
and increased 60-fold during the first 3 months follow-
ing delivery compared with non-pregnant females [17].
Hormone replacement therapy is reported to increase
the risk of PE by two- to four-fold [18,19]. However, at
variance with the oral route of administration, transdermal
oestrogen does not have a first pass effect through the
liver and it has been suggested that this might lead to less
risk of thrombosis [18,19]. Oral contraceptive therapy in-
creases the risk of PE by two- to five-fold [20]. However,
since the absolute risk of PE is low in young females, the
annual risk in users of oral contraceptives remains low at
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ing the first year of use. The type of progesteron affects
the risk of venous thrombosis, with a two fold higher risk
for contraceptives containing a third generation (desoges-
trel and gestodene) than a second generation (levonorges-
trel) progestogen [20].
Other medical disorders associated with increased risk
for PE include heart failure, ischemic stroke, acute re-
spiratory failure or intubation, sepsis, acute rheumatic
disease, and inflammatory bowel disease [10,13].
Diagnostic strategies
The diagnostic pathway of PE is guided by two princi-
ples. First, accurate and fast identification of patients
with PE is critical because PE is a potentially fatal condi-
tion and anticoagulation is associated with the risk of
major bleeding. A false diagnosis thus exposes patients
to unnecessary risk of death from PE or of bleeding which
can also be fatal. Second, the use of individual diagnostic
tests in isolation may lead to mismanagement of suspected
PE. For these reasons, integrated diagnostic approaches
that include a combination of different diagnostic tests are
preferred. Because use of a validated diagnostic work-up is
associated with a substantially diminished risk of compli-
cations [21], implementation of such standardized ap-
proaches is highly recommended.
Clinical probability assessment
In general, the initiating point for any diagnostic ap-
proach is the clinical suspicion that should guide the
choice of the initial test [22]. Prior to the development
of objective testing, the diagnosis of PE was largely based
on clinical history and physical examination. Unfortu-
nately, PE cannot be diagnosed or excluded on clinical
grounds as symptoms and signs are non-specific [23-25].
However, it has long been recognised that unexplained
dyspnoea and/or chest pain are present in about 97% of
the patients with proven PE and may be useful to raise
the suspicion of PE and to select patients for further diag-
nostic testing [8]. Therefore, in the diagnostic work-up of
PE, the information obtained from the clinical history and
a physical examination should be evaluated in conjunction
with additional data derived from readily available labora-
tory tests, such as chest radiography, electrocardiography,
and arterial blood gas analysis [26]. The combination of
clinical and laboratory data may either increase the clinical
suspicion of PE, or suggest alternative diagnoses [26]. Al-
though diagnostic strategies of PE may differ significantly
in different clinical contexts and special conditions, the
present Task Force recommends that pre-test clinical prob-
ability of PE must always be objectively assessed in each
patient, while D-dimer measurements should be deter-
mined if pre-test probability of pulmonary embolism is low
or intermediate. Diagnostic imaging of the chest should beused to assess post-test probability of PE in most patients.
Further testing is necessary when the post-test probability
of PE is neither sufficiently low nor sufficiently high to per-
mit therapeutic decisions.
Pre-test clinical probability of pulmonary embolism
A thorough clinical evaluation is the key step in raising
the suspicion of the disease and setting up appropriate
diagnostic strategies. A recent study [27] has shown that
the vast majority of patients with pulmonary embolism
has at least one of four symptoms which, in decreasing
order of frequency, are: a) sudden onset dyspnoea; b)
chest pain; c) fainting (or syncope); d) haemoptysis.
Although the diagnostic yield of individual clinical symp-
toms, signs and common laboratory tests is limited, the
combination of these variables, either by empirical assess-
ment or by a prediction rule, can be used to stratify patients
by risk of pulmonary embolism (low, intermediate or high).
The results of two broad prospective studies in the 1990s
[8,28] indicate that physicians’ estimates of the clinical like-
lihood of PE, even if based on empirical assessment, do
have predictive value. Three objective scoring systems have
been tested prospectively and validated in large scale clin-
ical trials: the Wells score [29], the Geneva score [30] and
the Pisa score [8]. The three scoring systems perform rea-
sonably well in objectively assessing the clinical probability
of PE in outpatients or emergency room patients. The Pisa
score [8] seems to perform better than other scoring sys-
tems in hospitalized patients [31]. It appears that fully stan-
dardized scoring systems, such as the Wells [29] and the
Geneva [30] scores, with no implicit evaluation of symp-
toms (e.g. dyspnoea and chest pain) or simple instrumental
findings (e.g. ECG and chest radiograph), did not perform
better than subjective clinical judgment of experienced phy-
sicians in the PIOPED [28] and the PISA-PED [8] studies.
Conversely, interpretation of chest radiographs in patients
with suspected PE, as in the Pisa score [8], necessitates
a certain level of clinical experience and it is hard to
standardize. Whatever scoring method is used, pre-test
clinical probability categorizes patients into subgroups with
different prevalence of PE, and the positive and negative
predictive value of various objective tests is strongly condi-
tioned by the independently assessed pre-test clinical prob-
ability [32]. Accordingly, recent international guidelines
[33] recommend that the clinical probability of the disease
should be assessed in each patient with suspected PE before
any further objective testing occurs. Future research is
needed to develop standardized models, of varying degrees
of complexity, which may find applications in different clin-
ical settings to predict the probability of PE.
D-dimer testing
Fibrin D-dimer is a degradation product of cross-linked
fibrin, and its levels are elevated in the presence of
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[34]. Consequently, a normal (usually below a threshold
of 500 μg/ml) D-dimer level has a high negative predict-
ive value for PE or deep vein thrombosis [34,35]. How-
ever, endogenous fibrin production may be increased in
a wide variety of conditions including, cancer, inflamma-
tion, infection, pregnancy and chronic illnesses [34,35].
Thus, elevated plasma D-dimer levels have a low positive
predictive value for PE and deep vein thrombosis [34,35].
The value of D-dimer measurement in the diagnostic
work-up of each patient must be considered according
to the determined clinical probability of PE and the sen-
sitivity of the particular method of D-dimer measure-
ment employed [34,35]. A negative D-dimer test result,
measured by any method, in combination with a low
probability clinical assessment, excludes PE with accuracy
[34,35]. An intermediate clinical probability also would ex-
clude PE with reasonable certainty if D-dimer is measured
by a high-sensitivity ELISA method [35]. It has been shown
that the 3-month risk of PE or deep vein thrombosis in un-
treated patients with a negative D-dimer and a low or
intermediate clinical probability is 1% [35]. Conversely, if
clinical assessment results in a high probability of PE, a
concomitant negative D-dimer test does not exclude PE
[35]. The number of patients with suspected PE in whom
D-dimer must be measured to exclude one pulmonary em-
bolism episode ranges between three (in the emergency de-
partment) and 10 (in hospitalized patients). Therefore, it
appears recommendable to consider D-dimer measure-
ment in the diagnostic work-up of pulmonary embolism
only in outpatients or in patients in the emergency depart-
ment with low or intermediate levels of clinical probability.
The sensitivity of D-dimer testing for PE increases with the
extent of pulmonary embolism [34,35]. D-dimer concen-
trations are the highest in patients with PE involving the
pulmonary trunk and lobar arteries and with perfusion
scan defects involving 50% of the pulmonary circulation.
Diagnostic imaging of the chest: post-test probability of
pulmonary embolism
In recent years, the contribution of computed tomographic
angiography (CTA) to the diagnosis of pulmonary embol-
ism has greatly increased as a consequence of the extraor-
dinary advancement in CTA technology. Multidetector
CTA, which outlines thrombi in the pulmonary arteries
with intravenous contrast medium, has become the most
widely used technique for the diagnosis or exclusion of PE,
and has almost replaced lung scanning as a screening test
and conventional pulmonary angiography as the reference
standard for the diagnosis of acute PE [36].
CTA, however, does not escape the simple rule that
the combined use of the estimated clinical probability
and the results of one noninvasive test substantially in-
crease the accuracy of confirming or ruling out a disease,as compared with either assessment alone. As shown by
the PIOPED II trial [37], the predictive value of CTA is
high with a concordant clinical assessment, but additional
testing is necessary when clinical probability is inconsist-
ent with the imaging results. Several recent studies [38]
have shown a positive yield rate of CTA of 10% in patients
who are clinically suspected of PE. This may indicate that
the wide availability of CTA has led to an overuse of the
technique as a screening procedure for pulmonary embol-
ism in the emergency department. It has been suggested
that a substantial number of CTAs could be avoided by
adhering to the information derived from clinical evalu-
ation and D-dimer testing [38]. Of note, the positive pre-
dictive value of CTA varies with the extent of PE, being
97% with main or lobar pulmonary arteries abnormalities ,
68% with segmental, but only 25% with isolated subseg-
mental pulmonary artery abnormalities [39].
Perfusion (Q) lung scanning was introduced 40 years
ago as the first chest imaging method for the diagnosis
of PE. A normal Q scan excludes pulmonary embolism
with great accuracy (i. e. with high sensitivity and high
negative predictive value), whatever the pretest clinical
probability [33]. However, Q scanning was thought to be
poorly specific (low predictive positive value) for PE be-
cause common pulmonary diseases such as infections,
neoplasms and COPD, can produce decreased blood flow
to the affected regions. Ventilation (V) scanning was added
to Q scanning to increase the specificity of scintigraphy
[28]. This diagnostic approach is based on the flawed ex-
pectation that regions of the lung excluded from perfusion
by emboli maintain normal ventilation, thus giving rise to
V/Q mismatch [28]. This criterion for diagnosing PE is at
variance with the notion that ventilation is shifted away
from embolized lung regions. The concept that dead space
ventilation is not significantly increased in the course of
pulmonary embolism was widely held in respiratory patho-
physiology before the V/Q scanning approach was devel-
oped, as asserted by Comroe [40], who foresaw that
“decrease in wasted ventilation [ventilation to unperfused
or poorly perfused lung] helps the patient but hinders the
physician in diagnosis…”. This notion is in keeping with
the results of the PIOPED trial [28], in which it was shown
that a high-probability V/Q scan (Q defects without
matching V abnormalities) lacks sensitivity in diagnosing
PE, as it fails to identify 59% of pulmonary embolism pa-
tients (sensitivity 41%, specificity 97%). The combination
of clinical probability and V/Q scan results either confirms
or excludes pulmonary embolism in only 30% of patients.
The diagnostic value of the Q scan without V imaging was
reappraised in the PISA-PED study [8], in which Q scans
were read either as compatible with pulmonary embolism
when featuring wedge-shaped (segmental) perfusion defects
or not compatible with PE when featuring defects other
than wedge-shaped or normal perfusion. When compared
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approach has several advantages: a) Q scanning either
confirms or excludes the clinical suspicion of pulmon-
ary embolism, thus virtually eliminating nondiagnostic
examinations; b) the sensitivity of lung scintigraphy is
greatly increased (86% versus 41%) but with minor reduc-
tion of specificity (from 97% to 93%); c) the combination of
clinical probability and Q scanning results confirms or ex-
cludes pulmonary embolism in about 80% of patients [8].
More recently, the diagnostic performance of Q scan-
ning for pulmonary embolism was confirmed by examin-
ing 889 scans from the PIOPED II study [41]. PIOPED
II data [37] were used to test the hypothesis that reading
Q scans without V scans and categorizing the Q scan as
“PE present’, “PE absent” or “Q scan non-diagnostic” can
result in clinically useful sensitivity and specificity in a
high proportion of patients. The study has confirmed
that Q scan and CTA have comparable positive (85 and
86%, respectively) and negative (96 and 95%, respect-
ively) predictive values, with absence of non-diagnostic
readings for the Q scan [41]. Accordingly, in 2012 the
Society of Nuclear Medicine [33] revised the practice
guidelines for lung scintigraphy, reporting that “The
modified PIOPED II and PISAPED criteria using infor-
mation from chest radiograph and perfusion scans have
been shown to perform equivalently to those including
ventilation scintigraphy, with fewer nondiagnostic studies”.
Diagnostic strategies in different clinical contexts and
special conditions
Most clinicians and radiologists feel more comfortable
with an anatomical demonstration of whether a clot is
present than assessing the probability of pulmonary em-
bolism by looking at V/Q mismatches [28] or evaluating
the shape of a perfusion defect [8]. Furthermore, con-
trary to scintigraphy, in most hospitals, CTA is available
24 h a day, 7 days a week. However, CTA cannot be per-
formed in the whole population of patients suspected of
PE. As shown in the PIOPED II trial [37], about 50%
of the recruited patients did not undergo CTA because
of documented contraindications, such as renal failure,
allergy to the contrast agent, possible pregnancy, critical
illness, requirement of ventilator support or recent myo-
cardial infarction. In all these conditions, Q scanning
could be the preferred alternative approach to the diag-
nosis of PE. This approach is particularly important for
reproductive-age female patients in whom the breast ir-
radiation dose from CTA can be minimized by using the
Q scan as the first imaging test. It has been recently
shown that contrast medium-induced nephropathy is at
least as common as a diagnosis of PE after CTA [42].
Under circumstances in which clinical probability and
imaging test (CTA or scintigraphy) results are discord-
ant, further testing, such as lower limb compressionultrasonography, is required to either confirm or exclude
the diagnosis. Another practical approach could be to
image the pulmonary circulation with CTA if Q scan
was the first imaging test used or vice versa.
With the widespread use of CT, particularly for cancer
staging, diagnosis of incidental PE has become increas-
ingly common. Incidental PE was reported in about 3%
of thoracic scans in one meta-analysis with higher preva-
lence among hospitalized and cancer patients [43]. Of
note, retrospectively many of these patients has symp-
toms such as fatigue or breathlessness.Treatment
Risk-adapted therapeutic strategies
Pulmonary embolism represents a spectrum of syn-
dromes ranging from small peripheral emboli causing
pleuritic pain to massive PE resulting in cardiogenic
shock or cardiac arrest. Indeed, most patients with PE
present with normal haemodynamic condition; however,
some of them may rapidly deteriorate and manifest sys-
temic hypotension, cardiogenic shock, and sudden death
despite therapeutic levels of anticoagulation. Therefore,
risk stratification to identify such patients has emerged
as a critical component of care.
Severity index scores which allow clinical stratification
of patients with PE according to their prognosis have
been proposed [44,45]. According with their scores, pa-
tients with PE can be assigned to one of the following
different classes of risk: a) high-risk patients, who repre-
sent about 5% of all symptomatic patients, with about a
15% short-term mortality; these patients should be
treated aggressively with thrombolytic drugs or surgical
or catheter embolectomy [46]; b) low-risk patients, with
a short-term mortality of about 1%; they might benefit
from early discharge or even outpatient treatment [47];
c) intermediate risk patients, who represent about 30%
of all symptomatic patients and should be admitted to
hospital, with potential benefit of thrombolytic treat-
ment. Both low-risk and intermediate risk categories are
referred to as non-massive pulmonary embolism [24].
Apart from hemodynamic stabilization and reversal of
hypoxemia, the therapeutic goals for acute PE are pre-
vention of appositional thrombus growth, restoration of
pulmonary blood flow, and prevention of recurrences.
Therefore, in the absence of contraindications, paren-
teral anticoagulation is mandatory. The therapeutic op-
tions available include unfractionated heparin (UFH),
low-molecular-weight heparin (LMWH), fondaparinux.
When clinical suspicion of PE is high or moderate and
testing will not be completed within four hours, initial
anticoagulation, with consideration of the bleeding risk,
should be initiated before a definitive diagnosis is avail-
able [48].
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Patients with confirmed PE and hypotension (i.e. systolic
blood pressure <90 mmHg) who do not have a high
bleeding risk require immediate systemic thrombolytic
therapy because these patients are at an increased risk of
death. [48]. Systemic thrombolytic therapy is most com-
monly used, typically as 100 mg of tissue plasminogen
activator given as a two hour infusion [48]. Alternatively, if
expertise is available, thrombus removal may be achieved
by infusion of lower doses of thrombolytic drug directly
into the thrombus, by catheter based fragmentation and
aspiration of thrombus, by use of these two modalities to-
gether, or by surgical embolectomy (see below). While
there is strong evidence from randomized trials that sys-
temic thrombolysis accelerates resolution of PE, its ability
to save lives or reduces long term cardiopulmonary im-
pairment remains uncertain [48].
Therapeutic strategies in non-high risk patients
Treatment of patients with intermediate and low risk
(i.e. non massive embolism) has three phases: the initial
phase, the early maintenance phase, and the long-term
secondary prevention phase. In these categories of pa-
tients anticoagulation using LMWH or fondaparinux in
a weight-adjusted dose is considered the cornerstone of
the initial treatment [48 also for further references]. The
main advantage of LMWH is that they can be administered
subcutaneously in fixed weight-adjusted doses without
needing monitoring in most cases [49]. The mechanism of
action of these heparins is similar to that of unfractionated
heparin, but with a more pronounced effect on activated
factor X compared with thrombin. The clinical equivalence
of LMWH and unfractionated heparin for treating deep
vein thrombosis has been confirmed in a meta-analysis
[50]. By contrast with unfractionated heparin and LMWH,
which are derived from the porcine intestinal tract, fonda-
parinux is a synthetic compound which is almost identical
to the smallest natural component of heparin that can still
bind to antithrombin to specifically inhibit activated Factor
X. This drug is non-inferior to LMWH and unfractionated
heparin in patients with deep vein thrombosis and PE
[51,52]. Unfractioned heparin is preferable for patients with
a very high risk of bleeding or severe renal insufficiency
[51,52].
Long-term secondary prophylaxis and prevention
of recurrence
For intermediate and low risk patients with PE, inter-
national guidelines [48,53] recommend to start adminis-
tration of vitamin K antagonists (such as warfarin) as early
as the first or second day; UFH, LMWH or fondaparinux
therapy should be continued in conjunction for at least
five days and stopped when the international normalized
ratio is in the therapeutic range (2.0 to 3.0) for at least aday [48,53]. Alternatively, LMWH can be continued long
term, particularly in patients with cancer associated with
PE because of greater compatibility of LMWH with che-
motherapy, and difficulty in controlling vitamin k an-
tagonist therapy. Long term LMWH is also used for
treatment PE during pregnancy because vitamin k antago-
nists are teratogenic [48]. For PE secondary to reversible
risk factors, treatment with a vitamin K antagonists for
three months is recommended. After three months of
treatment, patients with unprovoked PE should be evalu-
ated for the risk-benefit ratio of extended therapy. In light
of the lasting increase in the risk of recurrence after the
initial occurrence of an “idiopathic” PE, we recommend
continuing treatment with a vitamin K antagonist for at
least three months. Provided anticoagulation is stable and
the risk of bleeding is low, indefinite continuation of this
therapy should be considered. Patients with PE and malig-
nancies should be treated with LMWH for the first three to
six months and they should subsequently receive lifetime
anticoagulation with vitamin K antagonists or LMWH.
Recently developed new oral anticoagulants (rivaroxa-
ban and dabigatran), that are directed against factor Xa or
thrombin, overcome some limitations of standard therapy,
including the need for injection and for dose adjustments
on the basis of regular monitoring [48,54,55]. These new
anticoagulants are as effective as conventional anticoagu-
lant therapy, and are associated with a lower risk of in-
tracranial bleeding but a higher risk of gastrointestinal
bleeding [54,55]. Dabigatran is preceded by initial heparin
therapy, whereas rivaroxaban does not require heparin
therapy but requires a higher dose for the first three weeks
of treatment [54,55]. Both are contraindicated in the pres-
ence of severe renal impairment and, due to the limited
experience, must be used cautiously to treat PE in patients
with advanced cancer or receiving cancer chemotherapy.
The decision to use one of these new drugs for the long
term treatment of PE is influenced by local availability and
licensing, whether their cost is covered by state or private
insurance plans, and patient and physician satisfaction
with current therapy.
Surgical and interventional treatment of pulmonary embolism
For patient with hypotension or shock in whom thromb-
olysis has failed or is absolutely contraindicated, surgical
embolectomy can be a lifesaving treatment option, provided
that the surgery can be performed on specialized center
[48]. Alternatively, catheter embolectomy or thrombus frag-
mentation may be considered, provided that there is ad-
equate experience with these modalities on site. Surgical
removal of pulmonary emboli is also generally recom-
mended in the case of patients who have free-floating
thrombi in the right atrium or ventricle and in the case
of those with impending paradoxical emboli through a
patent forame ovale [53]. Recent technical advances in
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larly the timely involvement of the cardiac surgeon as
part of an interdisciplinary approach to high-risk PE
may contribute to better postoperative outcomes.
Systematic use of venous filters to prevent PE recur-
rence is not recommended [48]. Venous filters may,
however, be indicated in exceptional cases if therapeutic
anticoagulation is absolutely contraindicated or a PE
has recurred despite adequate anticoagulation [48]. The
venous filter should be removed as soon as possible in
order to avoid secondary vena cava thromboses and
thromboembolisms.
Conclusions
Pulmonary embolism is a potentially life-threatening condi-
tion, difficult to diagnose in several patients. Misdiagnosis is
frequent particularly in elderly patients. Clinical sings of PE
are neither sensitive nor specific enough to rule in or out
the diagnosis. The choice of a diagnostic strategy for PE de-
pends on the pretest clinical probability of PE, the condition
of the patient, the availability of the necessary test, the risks
of testing, the risk of an inaccurate positive or negative diag-
nosis, and the cost. Clinical evaluation makes it possible to
classify patients into probability categories corresponding to
an increasing prevalence of PE, whether assessed by implicit
clinical judgment or by a validated prediction rule. Struc-
tured models to assess clinical probability so far developed
have different performances in patients of the emergency
department and in those who are hospitalized. Exclusion of
PE by clinical probability assessment and D-dimer spares
the cost and radiation of an imaging evaluation. CTA has
become the method of choice for imaging the pulmonary
vasculature when pulmonary embolism is suspected in rou-
tine clinical practice. Scintigraphy can be considered the
preferred alternative chest imaging technique for patients
with contraindication to CTA. If scintigraphy is used, elim-
inating the V scan can reduce cost and radiation load with
gain in diagnostic yield.Competing interests
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